Colloidal P32 chromic phosphate is administered by which route?

Colloidal P32 chromic phosphate is administered through the intraperitoneal route. This method is primarily used for the treatment of certain conditions such as malignant ascites in patients with peritoneal carcinomatosis. When delivered intraperitoneally, the colloidal particles localize in the peritoneal cavity, allowing for targeted radiation to cancerous cells while minimizing exposure to surrounding healthy tissues.

This route takes advantage of the distribution characteristics of the colloid, ensuring optimal uptake and prolonged residence time within the peritoneal cavity, which enhances the effectiveness of the treatment. Additionally, colloidal formulations are specifically designed to remain distributed in the targeted area for an extended duration, increasing the likelihood of delivering a therapeutic dose directly to malignant cells.